Delayed contrast enhancement cardiac magnetic resonance imaging in trastuzumab induced cardiomyopathy

BACKGROUND: Trastuzumab (Herceptin), an antagonist to the human epidermal growth factor 2 (HER2) receptor significantly decreases the rates of breast cancer recurrence and mortality by 50%. Despite therapeutic benefits, the risk of cardiotoxicity with trastuzumab ranges from 10–15% when administered...

Descripción completa

Detalles Bibliográficos
Autores principales: Fallah-Rad, Nazanin, Lytwyn, Matthew, Fang, Tielan, Kirkpatrick, Iain, Jassal, Davinder S
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2008
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2244612/
https://www.ncbi.nlm.nih.gov/pubmed/18272009
http://dx.doi.org/10.1186/1532-429X-10-5

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2244612/
https://www.ncbi.nlm.nih.gov/pubmed/18272009
http://dx.doi.org/10.1186/1532-429X-10-5

Ejemplares similares